What is HC Wainwright’s Estimate for AURA Q3 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Aura Biosciences in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will earn ($0.47) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ FY2027 earnings at ($1.64) EPS.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09).

Separately, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Price Performance

Shares of AURA stock opened at $5.94 on Wednesday. The firm’s 50-day simple moving average is $7.57 and its 200-day simple moving average is $8.62. Aura Biosciences has a 1-year low of $5.77 and a 1-year high of $12.38. The firm has a market cap of $296.71 million, a P/E ratio of -3.43 and a beta of 0.30.

Insider Activity

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the transaction, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 23,045 shares of company stock valued at $177,242 in the last three months. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors have recently bought and sold shares of the business. Barclays PLC lifted its holdings in shares of Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after acquiring an additional 43,897 shares in the last quarter. State Street Corp raised its position in Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after purchasing an additional 26,841 shares during the period. Geode Capital Management LLC lifted its stake in shares of Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after purchasing an additional 39,379 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Aura Biosciences in the third quarter worth about $1,037,000. Finally, Franklin Resources Inc. grew its stake in shares of Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after buying an additional 215,597 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.